C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.
| Revenue (TTM) | $35.04M |
| Gross Profit (TTM) | $30.25M |
| EBITDA | $-99.45M |
| Operating Margin | -397.90% |
| Return on Equity | -48.10% |
| Return on Assets | -19.30% |
| Revenue/Share (TTM) | $0.31 |
| Book Value | $2.01 |
| Price-to-Book | 1.53 |
| Price-to-Sales (TTM) | 10.64 |
| EV/Revenue | 5.2 |
| EV/EBITDA | -0.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2.80% |
| Shares Outstanding | $123.03M |
| Float | $94.51M |
| % Insiders | 0.84% |
| % Institutions | 103.10% |
Volatility is currently contracting
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide's Dual Mechanism of Action
Here is how C4 Therapeutics, Inc. (CCCC) and MacroGenics (MGNX) have performed compared to their sector so far this year.
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM) will be presented in a poster at the 23rd IMS Annual Meeting.
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.37 per share a year ago.
Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CCCC and any ticker you trade — then tracks every position and per-strategy win rate.
